Anixa Biosciences secures Canadian patent for its ovarian cancer vaccine
Canada granted Anixa Biosciences patent 3,005,025, which covers aspects of its ovarian cancer vaccine technology. The protection complements a US patent granted in July 2025. The release, distributed by PR Newswire, does not include financial terms or clinical results for the vaccine.
In 25 seconds
- Canada granted Anixa Biosciences patent 3,005,025 covering its ovarian cancer vaccine technology.
- The patent complements protection from a US patent granted in July 2025.
- The release does not include financial terms or clinical results for the vaccine.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.